Pancreatic cancer took Andy Lyons’ grandmother, mother, aunt, uncle, and brother. Could he prevent it from becoming his story, too?

Host Alisyn Camerota sits down with Andy to discuss his more than 20 years of surveillance through a familial pancreatic cancer research study. That vigilance made a life-changing difference in 2021, when his pancreatic cancer was detected early enough for him to undergo Whipple surgery just two weeks after diagnosis, followed by chemotherapy.

Today, Andy encourages anyone with a family history of pancreatic cancer to talk with their doctor about genetic testing.

PancChat is a collaboration produced by Let’s Win Pancreatic Cancer and PanCAN.

Resources:
Let's Win Pancreatic Cancer
PanCAN
Let's Win Clinical Trial Finder
PanCAN Clinical Trial Finder
Let's Win Doctor Finder
PanCAN Patient Services
Andy Lyon's Survivor Story
Andy Lyon's Survivor Video

Click here to view the episode transcript.

In this episode of PancChat, host Alisyn Camerota is joined by pancreatic neuroendocrine tumor, or PNET, patient Katie DeCarlo. Katie shares her experience living with stage IV cancer and how she has come to approach her diagnosis as a chronic condition she continues to manage while living her life to the fullest.

Katie shares her journey from diagnosis through treatment, including surgery, chemotherapy, liver ablation, and participation in a clinical trial. She reflects on what it means to manage PNET as a chronic condition, the emotional challenges of living with an ongoing diagnosis, and the importance of finding a supportive community. She also shares her optimism about the rapid advancements in PNET treatment and what they could mean for patients.

PancChat is produced in collaboration with Let’s Win Pancreatic Cancer and PanCAN.

Resources:

Let's Win Pancreatic Cancer
PanCAN
Let's Win Clinical Trial Finder
PanCAN Clinical Trial Finder
Let's Win Doctor Finder
PanCAN Patient Services

Not all pancreatic cancers are the same. While most patients are diagnosed with pancreatic adenocarcinoma, approximately 10% have pancreatic neuroendocrine tumors (PNETs). What makes PNETs different, and what does that mean for diagnosis, treatment, and care?

On this episode of PancChat, host Alisyn Camerota joins Dr. Diane Reidy-Lagunes, chief of the Division of Medical Oncology and vice president for oncology services at Duke University Health System, to explore the biology, symptoms, treatment, and outlook of PNETs.

Dr. Reidy-Lagunes explains why some PNETs can be monitored while others need treatment, how tumor grade helps guide care, and how expanding treatment options are helping many patients live for years – even with advanced disease. They also discuss emerging research and why a second opinion from a team with neuroendocrine expertise can help patients navigate their options.

PancChat is sponsored by Revolution Medicines and produced in collaboration with Let’s Win Pancreatic Cancer and PanCAN.

Resources:
Let's Win Pancreatic Cancer
PanCAN
Let's Win Clinical Trial Finder
PanCAN Clinical Trial Finder
Let's Win Doctor Finder
PanCAN Patient Services

Up to 95% of pancreatic cancer patients have a KRAS mutation in their tumor. For decades, it was considered impossible to target with a drug. What changed?

To get the latest information, host Alisyn Camerota is joined by Dr. Eileen O'Reilly, medical oncologist and Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering Cancer Center, to unpack what RAS and KRAS actually are, why this gene resisted treatment for so long, and what the recent approval of Rasonque™ (daraxonrasib) means for patients with metastatic pancreatic cancer.

Dr. O'Reilly explains the biology behind RAS signaling, the different mutation types found in pancreatic cancer (including G12D, G12V, and G12R), how the new class of RAS-targeting drugs works, what testing for a RAS mutation involves, and what "RAS wild type" means for the small subset of patients without a detectable mutation. She also shares her perspective on what this breakthrough means for the field after years of limited progress, and where research is headed next.

PancChat is produced in collaboration with Let's Win Pancreatic Cancer and PanCAN.
PancChat is sponsored by Revolution Medicines.

Resources:

FDA Approves RASONQUE™ (daraxonrasib) - PanCAN
The FDA Approves Rasonque™ (Daraxonrasib) - Let's Win
Daraxonrasib: What To Know About Common Side Effects

Let's Win Pancreatic Cancer
Pancreatic Cancer Action Network (PanCAN)
Let's Win Clinical Trial Finder
PanCAN Clinical Trial Finder
Let's Win Doctor Finder
PanCAN Patient Services

The U.S. Food & Drug Administration (FDA) just approved a treatment that doubled survival time for patients with metastatic pancreatic cancer — what does this landmark approval mean for you or a loved one?

To get the latest information, host Alisyn Camerota is joined by Dr. Brian Wolpin, a medical oncologist at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School.

Dr. Wolpin breaks down what the FDA's approval of Rasonque™ (daraxonrasib) means for patients, how the drug works differently from chemotherapy, who's eligible to receive it, what side effects look like and how they're managed, and what's next as researchers explore other types of RAS inhibitors, novel combinations, different stages of disease, and more.

PancChat is produced in collaboration with Let's Win Pancreatic Cancer and PanCAN.

Thanks to our sponsor, Revolution Medicines.

Resources:
FDA Approves RASONQUE™ (daraxonrasib) - PanCAN
The FDA Approves Rasonque™ (Daraxonrasib) - Let's Win
Daraxonrasib: What To Know About Common Side Effects

Let's Win Pancreatic Cancer
Pancreatic Cancer Action Network (PanCAN)
Let's Win Clinical Trial Finder
PanCAN Clinical Trial Finder
Let's Win Doctor Finder
PanCAN Patient Services

Diabetes and pancreatic cancer often go hand in hand. Between 30 to 50% of patients have diabetes or prediabetes at diagnosis, and another 40% develop it during treatment.

To get the latest information, host Alisyn Camerota is joined by endocrinologist and Director of the Duke Onco-Endocrinology Program at the Duke Center for Cancer Immunotherapy, Dr. Afreen Shariff, an Associate Director for the Cancer Therapy Toxicity Program and a member of the faculty in the Division of Endocrinology, Diabetes, and Metabolism at Duke University School of Medicine.

In this episode, Dr. Shariff discusses managing pancreatic cancer and diabetes, and how surgery, chemotherapy, and radiation can all affect blood sugar as a direct, on-target effect of treatment. She emphasizes working with an endocrinologist and oncologist to help control diabetes during and after treatment.

Her advice: get a clear diagnosis, know your numbers, and don't hesitate to bring up blood sugar concerns with your oncology team.

PancChat is produced in collaboration with Let's Win Pancreatic Cancer and PanCAN.

This episode is sponsored by Revolution Medicines.

For more information, visit letswinpc.org and pancan.org.

RESOURCES:

Let's Win's Diabetes Section
PancCAN Diabetes and Pancreatic Cancer
PanCAN Patient Services
Let's Win Doctor Finder
Let's Win Clinical Trial Finder
PanCAN Clinical Trial Finder

Almost one in four people diagnosed with pancreatic cancer are also diagnosed with diabetes. In this episode of PancChat, host Alisyn Camerota talks with Dr. Suresh Chari, professor of medicine at MD Anderson Cancer Center and principal investigator for the PanCAN Early Detection Initiative, about the complex relationship between diabetes and pancreatic cancer.

Dr. Chari explains why new-onset diabetes can be an early warning sign for pancreatic cancer, why a sudden rise in blood sugar alongside unexplained weight loss is a pattern worth watching, and why early detection remains one of the biggest challenges in pancreatic cancer research. He also shares an update on the clinical trials underway — including AI-assisted imaging — aimed at catching pancreatic cancer earlier in people with new-onset diabetes.

This episode is sponsored by Revolution Medicines.

To learn more about pancreatic cancer support and resources, visit letswinpc.org and pancan.org.

Resources:

Let's Win Diabetes Info
PanCAN Diabetes Info
Let's Win Diabetes and Pancreatic Cancer Awareness Risk Quiz
PanCAN Patient Services
The Diabetes and Pancreatic Cancer Connection

With one new drug against the KRAS mutation on the path to FDA approval, what is the status of other KRAS drugs, as well as different types of treatment?

To get the latest information, host Alisyn Camerota is joined once again by Dr. Allyson Ocean, medical oncologist and director of the Pancreatic Cancer Research Program at Weill Cornell Medicine, and a co-founder of Let's Win, along with Dr. Anna Berkenblit, Chief Scientific and Medical Officer for PanCAN, who brings more than two decades of experience in the research and clinical development of novel anticancer therapies.

Together, they discuss the status of pancreatic cancer vaccine research, walk through what a drug's journey from idea to approval actually looks like, and explain in plain terms what separates a phase 1 clinical trial from a phase 2 or phase 3 trial — and why every phase matters for patients considering enrollment.

This episode is brought to you by our sponsor, Revolution Medicines.

To learn more about the latest breakthroughs in pancreatic cancer treatment, visit letswinpc.org and pancan.org.

PancChat is produced in collaboration with Let's Win Pancreatic Cancer and PanCAN.